* ASX-listed shares of AVITA Medical AVH.AX RCEL.O fall as much as 20.2% to A$3.470
** Stock last down about 18.8%, set for deepest one-day decline since Oct 2023
** Regenerative medicine firm cuts forecast for the fourth time in five quarters
** Says it expects Q4 commercial revenue of about $18.4 mln, compared to its prior guidance range of $22.3 mln to $24.3 mln
** Stock hits lowest price level since mid-Nov
** About 2 mln shares change hands, highest since mid-Aug 2022
** Stock fell 0.9% in 2024
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。